Nathan,
I hope this finds you well. Writing to provide a periodic update on the status of the conditions precedent to funding under the Senior Secured Credit Facility Commitment Letter dated March 8, 2025 (Ref. SC-2025-0312-AC) among Ardent Apex Holdings Inc., Ardent Apex Merger Sub Inc., and Stonebridge Credit Partners LLC, as lead arranger and administrative agent, in connection with the acquisition of Luminex Systems Holdings Inc. by Ardent Apex Holdings Inc. via reverse triangular merger pursuant to the Agreement and Plan of Merger dated March 24, 2025.
As a reminder, this relates to the $1,400,000,000 senior secured credit facility, comprising a $1,200,000,000 Term Loan B and a $200,000,000 Revolving Credit Facility.
**1. Regulatory Filing Status Update**
Set forth below is the current status of all regulatory approvals constituting conditions precedent to closing and funding:
(a) **HSR Act Filing.** The HSR premerger notification was filed on March 28, 2025 (Transaction No. HSR-20250328-4192), and the filing fee of $2,390,000 has been paid. The matter was cleared to the FTC pursuant to the DOJ/FTC clearance allocation on April 2, 2025, and the initial 30-day waiting period is set to expire on April 27, 2025. Based on communications with FTC staff and the competitive overlap in the procurement-automation SaaS space between Luminex (approximately 18% market share) and Vectis Solutions LLC, an Ardent Capital Fund II portfolio company (approximately 7% market share; combined approximately 25%), the deal team anticipates the FTC will issue a Second Request on or around April 25, 2025. Our antitrust partner, Elaine Forsythe, is leading the antitrust workstream, and the team is actively preparing for Second Request compliance. A draft timing agreement letter to the FTC is being prepared. While the Second Request process is expected to extend the regulatory timeline, the team is working toward resolution within the current outside date framework.
(b) **CFIUS Review.** A voluntary joint notice was filed on April 4, 2025 (Tracking No. CFIUS-2025-0087). The filing was made on the basis that Luminex Systems Inc. (the U.S. operating subsidiary) holds contracts with three U.S. federal agencies — the Department of Defense (logistics software module), the Department of Energy (procurement platform), and the GSA (enterprise license) — constituting covered transactions under 31 C.F.R. Part 800. The 45-day review period expires on May 19, 2025. There has been no indication to date of escalation to a full investigation. We will update all parties promptly upon receipt of any communication from the Committee.
(c) **Swiss Competition / SECO (Lex Koller).** A notification was filed on April 7, 2025 with the Swiss Competition Commission and SECO (File No. 32-0973). Combined Swiss revenues exceed the CHF 100 million threshold under the Cartel Act (KartG). The matter is currently in Phase I review. Local counsel Breitfeld Hess & Partner AG (Dr. Lukas Breitfeld) is monitoring.
(d) **German Federal Cartel Office (Bundeskartellamt).** The filing was submitted on April 9, 2025 (File No. B6-34/25). Jurisdictional thresholds are met on the basis that Veltronix GmbH reported 2024 German revenue of €67,000,000 and Vectis GmbH reported German revenue of €12,000,000, with combined figures exceeding the €500 million worldwide and €25 million domestic thresholds under GWB §35. The matter is currently in Phase I review (one-month review period). Local counsel Wendt Schäfer Rechtsanwälte PartG mbB (Dr. Katarina Wendt) is managing the filing.
(e) **EU Foreign Subsidies Regulation (FSR).** A notification was filed on April 11, 2025 (Case No. FSR.M.2025-0412). The filing was triggered on the basis that EU turnover exceeds €500 million and foreign financial contributions exceed €50 million in the aggregate, including contributions attributable to Ardent LP's limited-partner base of sovereign wealth and state-affiliated pension funds. The preliminary review period of 25 business days is currently running. Breitfeld Hess & Partner AG is coordinating.
**2. Transaction Document Status**
The Merger Agreement was executed on March 24, 2025, and execution counterparts have been exchanged between Calderwood & Harkness and seller's counsel, Caldwell, Raines & Sheppard LLP (Patricia Okonkwo). Disclosure schedules have been delivered and are under review; Buyer's comments on the Seller's disclosure schedules have been transmitted to CRS.
The draft credit agreement has been circulated among the lending group (Stonebridge, Birchwood Capital Finance LLC, and Ironvale Credit Fund III LP). We would expect comments from the co-lenders to be consolidated and returned at your convenience (see request below).
The draft Guarantee and Collateral Agreement is being finalized and contemplates a first-priority lien on substantially all assets of Luminex Holdings and its domestic subsidiaries, together with a 65% pledge of first-tier foreign subsidiary equity.
The Intercreditor Agreement between Stonebridge (as senior representative) and Crestline Mezzanine Partners II LP (as subordinated representative) is in advanced draft form. We can confirm that the $300,000,000 subordinated notes are contractually subordinated to the Senior Secured Credit Facility.
**3. Other Conditions Precedent — Status Summary**
- **R&W Insurance:** The representations and warranties insurance policy is being bound with Grandview Specialty Insurance Company (Policy No. GSI-RWI-2025-04821) through Ashbury Risk Advisors LLC (Philip Navarro). The policy carries a $420,000,000 policy limit with a $14,000,000 retention (50/50 buyer/seller split) and an estimated premium of $8,400,000.
- **Escrow Agreement:** The Escrow Agreement with Continental Fiduciary Trust Company is substantially finalized (Escrow Account Ref. CFT-ESC-2025-7894). The escrow amount is $140,000,000 (5% of deal value), to be held for 18 months.
- **Solvency Certificate:** The form of solvency certificate to be delivered by the CFO of the surviving corporation at closing has been prepared and circulated to the Ardent team for review.
- **Equity Commitment Letter:** The Ardent Capital Partners III LP equity commitment of $695,980,000 is in place.
- **Co-Investment Commitments:** Co-investment agreements have been executed with Northvale Sovereign Holdings Ltd. ($200,000,000) and Summit Ridge Capital Partners LP ($100,000,000).
- **Management Rollover:** Rollover agreements for management participants (aggregate rollover of approximately $405,020,000) are being finalized. Key participants include Dr. Stefan Kessler (CEO, $142,800,000 rollover), Annelise Gruber (CFO, $58,800,000 rollover), and Dr. Markus Vogt (CTO, $58,520,000 rollover).
- **Legal Opinion / 10b-5 Letter:** Calderwood & Harkness's legal opinion and 10b-5 negative assurance letter (if required by the lending group) are in preparation and will be in deliverable form prior to closing.
**4. Anticipated Closing Timeline**
The target estimated closing remains Q3 2025 (July–August 2025), subject to regulatory approval timelines. The most significant variable is the anticipated HSR Second Request process and completion of the CFIUS review. The Outside Date under the Merger Agreement is September 10, 2025, with a three-month extension available (to December 10, 2025) if the sole unsatisfied condition at that time is regulatory approval. Based on current trajectory, the deal team believes a Q3 2025 closing remains achievable assuming no material regulatory obstacles beyond the anticipated Second Request.
**5. Next Steps**
We would appreciate it if Stonebridge and the co-lenders (Birchwood and Ironvale) could provide consolidated comments on the draft credit agreement at their earliest convenience. Calderwood & Harkness will provide further updates following the expiration of the HSR initial waiting period on April 27, 2025, and upon receipt of any communication from CFIUS.
Please let us know if it would be helpful to arrange a call with the broader deal team — including James Prentice, the Ardent Capital team, and the lending syndicate — to discuss any open items. We are also maintaining a Regulatory Conditions & Timetable Tracker internally and can share a redacted version if that would be useful.
Thank you, and please don't hesitate to reach out with any questions.
Best regards,
Ryan Kowalski Associate, Mergers & Acquisitions Calderwood & Harkness LLP 7 Times Square New York, NY 10036 Direct: (212) 555-4738 rkowalski@calderwoodharkness.com Calderwood & Harkness Matter No. 1001-00004
---
*CONFIDENTIALITY NOTICE: This email and any attachments are for the exclusive and confidential use of the intended recipient. This communication may contain information that is privileged, confidential, and exempt from disclosure under applicable law, including attorney-client privilege and/or work product doctrine. If you are not the intended recipient, any use, dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this email in error, please notify the sender immediately by reply email and permanently delete the original message and all copies. Thank you.*